Nektar Therapeutics Share Price & Technical Analysis
NKTR · $66.61 (-2.87%)
Healthcare / Biotechnology
$66.61
-2.87%
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-22% return in May, -15% avg return in past 3 year May month.
73% return in 2026, 59% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 85% | 6% | 16% | -22% | – | – | – | – | – | – | – | 73% |
| 25 | -14% | 2% | -21% | 15% | -10% | 132% | -13% | 40% | 96% | 13% | 4% | -34% | 212% |
| 24 | -4% | 29% | 29% | 58% | -13% | -5% | 7% | -4% | 3% | -8% | -6% | -19% | 67% |
| 23 | 19% | -50% | -51% | 7% | -22% | -6% | -6% | 10% | 1% | -18% | 3% | 12% | -102% |
| 22 | -18% | -8% | -48% | -23% | -16% | 10% | 6% | 1% | -18% | 16% | -27% | -19% | -146% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.59B
P/E ratio
—
52W high
$109.0
52W low
$7.99
Volume
5,48,015
Beta
1.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Nektar Therapeutics share price today?
- Nektar Therapeutics (NKTR) last traded around $66.61 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NKTR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NKTR. Download the app for real-time alerts.
- How can I analyze Nektar Therapeutics stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.